Epitalon vs SS-31 (Elamipretide)
Overview
Epitalon and SS-31 (Elamipretide) are both anti-aging & longevity peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Epitalon and SS-31 (Elamipretide) across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Epitalon | SS-31 (Elamipretide) | |
|---|---|---|
| Category | Anti-aging & Longevity | Anti-aging & Longevity |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | Research use only |
| Typical dosage | 5-10 mg | Clinical trials ongoing |
| Frequency | cycle | research |
| Reported benefits | Areas studied (research-reported, not established efficacy): telomerase activation and telomere elongation in human cell lines (PMID 12937682; DOI 10.1007/s10522-025-10315-x); increased melatonin synthesis and circadian effects in a small human study; lower overall and cardiovascular mortality in a 12-15 year single-lab trial that used pineal extract (epithalamin), not synthetic AEDG (PMID 17426848, 22451889). No independent multi-center RCTs; not FDA-approved. | Enhanced mitochondrial function, reduced oxidative stress, potential heart failure treatment |
| Reported side effects | Khavinson-group trials reported no serious adverse events (e.g., n=162 retinitis pigmentosa trial, PMID 12195242), but these are the only controlled safety data and remain unreplicated. Community use reports mild injection-site reactions. Theoretical concern: telomerase activation is a hallmark of most cancers, and a 2025 review (PMC11943447) notes carcinogenic potential is unstudied. No human pharmacokinetic or drug-interaction data. | Clinical trials. Side effects under study |
Key differences
Primary use. Epitalon is categorised under Anti-aging & Longevity, while SS-31 (Elamipretide) falls under Anti-aging & Longevity. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Epitalon: not FDA-approved; compounding permitted with a prescription as of April 2026. SS-31 (Elamipretide): not FDA-approved; treated as a research compound.
Dosing. Epitalon is typically dosed at 5-10 mg (cycle). SS-31 (Elamipretide) is typically dosed at Clinical trials ongoing (research).
Can you stack them?
Some protocols combine peptides, but stacking Epitalon and SS-31 (Elamipretide) has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Epitalon and SS-31 (Elamipretide)?
- Epitalon and SS-31 (Elamipretide) are both anti-aging & longevity peptides, but they differ in mechanism, dosing, and regulatory status. Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas SS-31 (Elamipretide) is not FDA-approved; generally classified as a research compound.
- What is Epitalon used for?
- Longevity, telomere support.
- What is SS-31 (Elamipretide) used for?
- Mitochondrial optimization.
- Can you take Epitalon and SS-31 (Elamipretide) together?
- Some users combine peptides within a single protocol, but stacking Epitalon and SS-31 (Elamipretide) has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Epitalon or SS-31 (Elamipretide) FDA-approved?
- Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026). SS-31 (Elamipretide) is not FDA-approved; generally classified as a research compound.
Read the full articles
- Epitalon — full monograph: mechanism, research, dosing & references
- SS-31 (Elamipretide) — full monograph: mechanism, research, dosing & references